Ovid Therapeutics (OVID) Long-Term Investments (2021 - 2026)

Ovid Therapeutics has reported Long-Term Investments for 6 years, with the latest figure at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 51.81% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (down 51.81% YoY), and the FY2025 full-year result was $42.0 million, changed N/A from the prior year.
• Long-Term Investments for Q1 2026 stood at $10.1 million, down from $42.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $42.0 million in Q4 2025, with the low at $2.2 million in Q2 2022.
• Historically, Long-Term Investments has averaged $15.7 million across 5 years, with a median of $17.0 million in 2023.
• Annual changes were most pronounced in 2023 — Long-Term Investments jumped 639.07% — and 2026, when it sank 51.81%.
• Ovid Therapeutics' Long-Term Investments stood at $5.6 million in 2022, then jumped by 213.49% to $17.6 million in 2023, then gained by 19.85% to $21.1 million in 2024, then jumped by 98.63% to $42.0 million in 2025, then slumped by 75.99% to $10.1 million in 2026.
• The last three Long-Term Investments figures came in at $10.1 million (Q1 2026), $42.0 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.